RxDoctor Payments Data

Michael Mavencamp, OD

Optometrist · Fairbanks, AKNPI 1760541676

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,375 of the $1,980 with a category attached, or 69.4%. 12 manufacturers reported payments, led by Alcon at 50.9% of the total. Reporting peaked in 2021 at $857 and has fallen 83.3% since, to $143 in 2025.

$1,980in general payments, 2019–2025

Across 40 payments — averaging $49.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sun Pharmaceutical Industries Inc.$233
  • Mallinckrodt Hospital Products Inc.$197
  • Novartis$159
  • Amgen$125
  • Oyster Point Pharma, Inc.$75
  • plus $182 from 6 others

What the payments were for

  • Speaking & faculty fees$60531%
  • Food & beverage$1,37569%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,980 in reported general payments places this provider in the 80th percentile of 163 optometrist providers in Alaska.

See all optometrist providers in Alaska

Medicare billing

Part B allowed, 2024
$75,638
Medicare patients
286
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine40$30,621
XiidraLifitegrast17$25,766
RestasisCyclosporine12$21,535
LumiganBimatoprost31$21,054
TyrvayaVarenicline Tartrate11$7,182
Loteprednol Etabonate29$6,642
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha24$338
Timolol Maleate13$69
Latanoprost15$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$64$42,58843 claims
Bausch & Lomb Americas Inc.Xiidra$19$25,76617 claims
Oyster Point Pharma, Inc.Tyrvaya$75$7,18211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 163 optometrist providers in Alaska.

Other optometrist in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →